AVITA Medical director receives stock awards

AVITA Medical, Inc. director Jan Stern Reed reported equity awards consisting of restricted stock units and options.

Rhea-AI Filing Summary

AVITA Medical, Inc. director Jan Stern Reed reported equity awards consisting of restricted stock units and options. Reed received 22,214 restricted stock units, each representing one share of common stock, that vest 12 months after the January 20, 2026 grant date and were subject to stockholder approval obtained on June 3, 2026.

On the same grant date, Reed was also granted 16,133 stock options to buy 16,133 shares of common stock at an exercise price of $3.77 per share, with an expiration date of January 20, 2036, also approved by stockholders on June 3, 2026. Following the equity award, Reed directly holds 73,225 shares of common stock, including unvested RSUs.

Insider Trade Summary

Grant/Award: 38,347 shares

Grant/Award 2 txns

Insider REED JAN STERN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	16,133	$0.00	$0.00
Grant/Award	Common Stock	22,214	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 16,133 contracts (Direct); Common Stock — 73,225 shares (Direct)

Footnotes (3)

1. F1. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
2. F2. Includes unvested RSUs.
3. F3. On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

Key Figures

RSUs granted: 22,214 units RSU vesting schedule: 12 months after grant Options granted: 16,133 options +3 more

6 metrics

RSUs granted 22,214 units Restricted stock units granted on January 20, 2026

RSU vesting schedule 12 months after grant Vesting based on January 20, 2026 grant date

Options granted 16,133 options Stock options to buy common stock granted January 20, 2026

Option exercise price $3.77 per share Exercise price equal to Nasdaq closing price on grant date

Option expiration January 20, 2036 Expiration date for 16,133 stock options

Shares held after award 73,225 shares Total common shares directly held after transactions

Key Terms

restricted stock units, RSUs, Stock Options (Right to Buy), exercise price, +1 more

5 terms

restricted stock units financial

"Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Stock Options (Right to Buy) financial

"Stock Options (Right to Buy)"

exercise price financial

"an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"with an expiration date of January 20, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AVITA Medical (RCEL) director Jan Stern Reed acquire in this Form 4?

Director Jan Stern Reed received equity compensation, including 22,214 restricted stock units and 16,133 stock options. The RSUs convert into common shares after vesting, while the options allow future share purchases at a fixed $3.77 exercise price.

How many AVITA Medical (RCEL) shares does Jan Stern Reed hold after these awards?

After the reported awards, Jan Stern Reed directly holds 73,225 shares of AVITA Medical common stock. This figure includes unvested restricted stock units, reflecting Reed’s total direct equity interest reported in this filing.

When do Jan Stern Reed’s AVITA Medical (RCEL) RSUs vest?

The 22,214 restricted stock units granted to Jan Stern Reed vest 12 months after the January 20, 2026 grant date. Once vested, each RSU entitles Reed to receive one share of AVITA Medical common stock.

What are the key terms of Jan Stern Reed’s AVITA Medical (RCEL) stock options?

Reed was granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share. These options are exercisable into 16,133 shares and expire on January 20, 2036, providing a long-dated incentive.

Were Jan Stern Reed’s AVITA Medical (RCEL) equity awards subject to stockholder approval?

Yes. Both the 22,214 restricted stock units and the 16,133 stock options were granted subject to AVITA Medical stockholder approval, which was obtained on June 3, 2026, confirming the awards’ authorization.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 07:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REED JAN STERN

(Last) (First) (Middle)

C/O AVITA MEDICAL 28159 AVENUE STANFORD

SUITE 220 - AVITA MEDICAL

(Street)

VALENCIA CALIFORNIA 91355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		A		22,214	A	(1)	73,225(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$3.77(3)	01/20/2026		A		16,133		01/20/2027	01/20/2036	Common Stock	16,133	$0	16,133	D

Explanation of Responses:

1. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

2. Includes unvested RSUs.

3. On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

	/s/ Nicole Kelsey, by power of attorney	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)